Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. MU
5. APGE
6. ABBV
7. DFTX
8. RGNX
9. GOOGL
10. LCO

Go back to Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy
(NASDAQ: FULC) Delayed: 3.83 +0.13 (3.51%)
Previous Close $3.70    52 Week High $ 
Open $3.69    52 Week Low $ 
Day High $3.85    P/E N/A 
Day Low $3.67    EPS $ 
Volume 555,634       

SANOFI (NASDAQ: SNY) Delayed: 41.27 -1.11 (2.62%)
Previous Close $42.38    52 Week High $44.76 
Open $40.91    52 Week Low $36.81 
Day High $41.32    P/E N/A 
Day Low $40.89    EPS $0.00 
Volume 1,666,584